RX 5902

Drug Profile

RX 5902

Alternative Names: RX-5902; Supinoxin

Latest Information Update: 24 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Korea Research Institute of Chemical Technology
  • Developer Rexahn Pharmaceuticals
  • Class Antineoplastics; Piperazines; Quinoxalines; Small molecules
  • Mechanism of Action RNA helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Preclinical Pancreatic cancer; Renal cell carcinoma
  • No development reported Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 24 Aug 2018 Rexahn Pharmaceuticals collaborates with Merck and Co to evaluate RX 5902 and pembrolizumab for Breast cancer
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 04 Jun 2018 Interim adverse events data from a phase I/II trial in Solid tumours released by Rexahn Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top